We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Uremic Toxin Removal With a New High Flux Cellulose Triacetate Membrane

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00230906
Recruitment Status : Completed
First Posted : October 3, 2005
Last Update Posted : December 28, 2007
Sponsor:
Collaborator:
Information provided by:

Study Description
Brief Summary:
Comparison of the uremic toxin removal by haemodialysis either with a low flux or a new high flux cellulose triacetate membrane

Condition or disease Intervention/treatment
Haemodialysis Procedure: Haemodialysis with either low or high flux membranes

Detailed Description:
Comparison of the uremic toxin removal by haemodialysis either with a low flux or a new high flux cellulose triacetate membrane

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Uremic Toxin Removal With a New High Flux Cellulose Triacetate Membrane
Study Start Date : January 2001
Study Completion Date : April 2002

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dialysis
U.S. FDA Resources

Arms and Interventions


Outcome Measures

Primary Outcome Measures :
  1. Concentration of uremic components after 3 weeks of haemodialysis

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Chronic haemodialysis patient
  • Serum albumin > 3.6 g/dl

Exclusion Criteria:

  • < 18 years
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00230906


Locations
Belgium
University Hospital Ghent
Ghent, Belgium, 9000
Sponsors and Collaborators
University Hospital, Ghent
Nissho Nipro Europe
Investigators
Principal Investigator: Raymond Van Holder, MD, PhD University Hospital, Ghent
More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00230906     History of Changes
Other Study ID Numbers: 2001/182
First Posted: October 3, 2005    Key Record Dates
Last Update Posted: December 28, 2007
Last Verified: December 2007